NAV

Tozadenant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tozadenant
DrugBank Accession Number
DB12203
Background

Tozadenant has been investigated for the basic science of Cocaine Dependence.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 406.5
Monoisotopic: 406.167476507
Chemical Formula
C19H26N4O4S
Synonyms
  • Tozadenant
External IDs
  • Syn115

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Following the oral administration of 240mg of tozadenant in healthy subjects, the mean plasma half-life was 15 hours.1

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazoles
Sub Class
Not Available
Direct Parent
Benzothiazoles
Alternative Parents
Methoxyanilines / Piperidinecarboxamides / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Morpholines / Tertiary alcohols / Heteroaromatic compounds / Thiazoles / Ureas
show 6 more
Substituents
1,3-benzothiazole / 1-piperidinecarboxamide / Alcohol / Alkyl aryl ether / Amine / Anisole / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
D9K857J81I
CAS number
870070-55-6
InChI Key
XNBRWUQWSKXMPW-UHFFFAOYSA-N
InChI
InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
IUPAC Name
4-hydroxy-N-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-4-methylpiperidine-1-carboxamide
SMILES
COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1

References

General References
  1. Mancel V, Mathy FX, Boulanger P, English S, Croft M, Kenney C, Knott T, Stockis A, Bani M: Pharmacokinetics and metabolism of [(14)C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers. Xenobiotica. 2017 Aug;47(8):705-718. doi: 10.1080/00498254.2016.1221164. Epub 2016 Sep 2. [Article]
PubChem Compound
11618368
PubChem Substance
347828487
ChemSpider
9793117
BindingDB
50011294
ChEBI
177494
ChEMBL
CHEMBL2105747
ZINC
ZINC000013986943
PDBe Ligand
9XW
PDB Entries
5olo

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentIdiopathic Parkinson's Disease2
2CompletedTreatmentParkinson's Disease (PD)1
2, 3CompletedTreatmentParkinson's Disease (PD)1
1CompletedBasic ScienceN/A, as Healthy Volunteers1
1TerminatedBasic ScienceHepatic Impairment1
1TerminatedOtherAbuse Potential1
0CompletedBasic ScienceDependence, Cocaine1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP1.96ALOGPS
logP1.48Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)10.76Chemaxon
pKa (Strongest Basic)0.13Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area87.16 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity108.26 m3·mol-1Chemaxon
Polarizability43.33 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:36 / Updated at December 01, 2022 11:27